{"id":"https://openalex.org/W2024838010","doi":"https://doi.org/10.1517/13543784.2015.971154","title":"Discontinued in 2013: oncology drugs","display_name":"Discontinued in 2013: oncology drugs","publication_year":2014,"publication_date":"2014-10-14","ids":{"openalex":"https://openalex.org/W2024838010","doi":"https://doi.org/10.1517/13543784.2015.971154","mag":"2024838010","pmid":"https://pubmed.ncbi.nlm.nih.gov/25315907"},"language":"en","primary_location":{"id":"doi:10.1517/13543784.2015.971154","doi":"https://doi.org/10.1517/13543784.2015.971154","is_oa":false,"landing_page_url":"https://doi.org/10.1517/13543784.2015.971154","pdf_url":null,"source":{"id":"https://openalex.org/S131064935","display_name":"Expert Opinion on Investigational Drugs","issn_l":"1354-3784","issn":["1354-3784","1744-7658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Investigational Drugs","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Robert Williams","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Robert Williams","raw_affiliation_strings":["Drug Development Office, Cancer Research UK , Angel Building, 407 St John Street, London EC1V 4AD , UK +44 203 469 6900 ; robert.williams@cancer.org.uk","Drug Development Office, Cancer Research UK , Angel Building, 407 St John Street, London EC1V 4AD , UK +44 203 469 6900"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Development Office, Cancer Research UK , Angel Building, 407 St John Street, London EC1V 4AD , UK +44 203 469 6900 ; robert.williams@cancer.org.uk","institution_ids":["https://openalex.org/I2801316944"]},{"raw_affiliation_string":"Drug Development Office, Cancer Research UK , Angel Building, 407 St John Street, London EC1V 4AD , UK +44 203 469 6900","institution_ids":["https://openalex.org/I2801316944"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I2801316944"],"apc_list":null,"apc_paid":null,"fwci":16.5622,"has_fulltext":false,"cited_by_count":63,"citation_normalized_percentile":{"value":0.98793351,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"24","issue":"1","first_page":"95","last_page":"110"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.5092999935150146,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.5092999935150146,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.31299999356269836,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.02710000053048134,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/drug-attrition","display_name":"drug attrition","score":0.7919999957084656},{"id":"https://openalex.org/keywords/anticancer-drug-development","display_name":"anticancer drug development","score":0.8410000205039978},{"id":"https://openalex.org/keywords/medication-discontinuation","display_name":"drug discontinuation","score":0.7379999756813049},{"id":"https://openalex.org/keywords/anticancer-agents","display_name":"anticancer agents","score":0.6370000243186951},{"id":"https://openalex.org/keywords/phase-iii-trial-failure","display_name":"phase III trial failure","score":0.7929999828338623},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.47699999809265137},{"id":"https://openalex.org/keywords/patient-stratification","display_name":"patient stratification","score":0.9580000042915344},{"id":"https://openalex.org/keywords/pharmacodynamic-markers","display_name":"pharmacodynamic biomarkers","score":0.8980000019073486},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.9229999780654907},{"id":"https://openalex.org/keywords/r-d-efficiency","display_name":"R&D efficiency","score":0.8410000205039978}],"concepts":[{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.7162786722183228},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6362467408180237},{"id":"https://openalex.org/C2779343474","wikidata":"https://www.wikidata.org/wiki/Q3109175","display_name":"Context (archaeology)","level":2,"score":0.6316373348236084},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.6217221617698669},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.44247111678123474},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4409894645214081},{"id":"https://openalex.org/C3020580240","wikidata":"https://www.wikidata.org/wiki/Q663272","display_name":"Expert opinion","level":2,"score":0.4375021755695343},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4232065975666046},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.39610421657562256},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.32507118582725525},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.32284218072891235},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1517/13543784.2015.971154","doi":"https://doi.org/10.1517/13543784.2015.971154","is_oa":false,"landing_page_url":"https://doi.org/10.1517/13543784.2015.971154","pdf_url":null,"source":{"id":"https://openalex.org/S131064935","display_name":"Expert Opinion on Investigational Drugs","issn_l":"1354-3784","issn":["1354-3784","1744-7658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Investigational Drugs","raw_type":"journal-article"},{"id":"pmid:25315907","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25315907","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on investigational drugs","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.6240000128746033,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":14,"referenced_works":["https://openalex.org/W1895993106","https://openalex.org/W1967105697","https://openalex.org/W1968779484","https://openalex.org/W1974897228","https://openalex.org/W1997362383","https://openalex.org/W2035140525","https://openalex.org/W2035866144","https://openalex.org/W2058298068","https://openalex.org/W2100053266","https://openalex.org/W2127180214","https://openalex.org/W2136652669","https://openalex.org/W2144268912","https://openalex.org/W2166550586","https://openalex.org/W2169585233"],"related_works":["https://openalex.org/W2035866144","https://openalex.org/W2547441676","https://openalex.org/W4401715793","https://openalex.org/W2057335441","https://openalex.org/W2158713870","https://openalex.org/W2020930678","https://openalex.org/W2172258043","https://openalex.org/W4286298900","https://openalex.org/W2793917881","https://openalex.org/W2547330766"],"abstract_inverted_index":{"Introduction:":[0],"Attrition":[1],"in":[2,30,60,74,84,104,133,150,178,181],"clinical":[3,171,182],"development":[4,50,136,183],"is":[5],"widely":[6],"recognised":[7],"as":[8,143],"a":[9],"key":[10],"factor":[11],"negatively":[12],"impacting":[13],"overall":[14,186],"R&D":[15,36,187],"efficiency.":[16,188],"Gaining":[17],"an":[18,43,176],"understanding":[19],"of":[20,45,49,51,66,87,90,99,109,125,130,152,162,170,185],"the":[21,56,63,82,85,100,110,148,160],"reasons":[22,46,138],"for":[23,47,119,139,154],"candidate":[24],"failure":[25],"may":[26,173],"lead":[27,174],"to":[28,175],"improvements":[29],"success":[31,179],"rates":[32,180],"and":[33,166,184],"return":[34],"on":[35,81],"investment.":[37],"Areas":[38],"covered:":[39],"This":[40],"report":[41],"provides":[42,79],"analysis":[44,72],"discontinuation":[48],"40":[52],"drugs":[53,97],"dropped":[54],"from":[55,156],"global":[57],"oncology":[58],"pipeline":[59],"2013":[61,101],"-":[62],"largest":[64,123],"number":[65,124],"terminations":[67,127],"reported":[68,142],"since":[69],"this":[70],"annual":[71],"began":[73],"2005.":[75],"The":[76,122],"article":[77],"also":[78],"discussion":[80],"observations":[83],"context":[86],"contemporary":[88],"views":[89],"anticancer":[91],"drug":[92,126],"development.":[93,107],"Expert":[94],"opinion:":[95],"Twelve":[96],"(30%":[98],"discontinuations)":[102],"failed":[103],"Phase":[105,134],"III":[106],"None":[108],"pivotal":[111],"trials":[112],"investigating":[113],"these":[114],"agents":[115],"incorporated":[116],"molecular":[117],"biomarkers":[118,165,167],"patient":[120],"stratification.":[121],"(20":[128],"out":[129],"40)":[131],"occurred":[132],"I":[135],"with":[137],"termination":[140],"commonly":[141],"strategic":[144],"or":[145],"undisclosed.":[146],"Raising":[147],"bar":[149],"terms":[151],"requirements":[153],"progression":[155],"preclinical":[157],"development,":[158],"including":[159],"identification":[161],"robust":[163],"pharmacodynamic":[164],"potentially":[168],"predictive":[169],"benefit":[172],"increase":[177]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":9},{"year":2018,"cited_by_count":11},{"year":2017,"cited_by_count":8},{"year":2016,"cited_by_count":9},{"year":2015,"cited_by_count":3}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2016-06-24T00:00:00"}